AURX
vs
S&P 500
AURX
S&P 500
Over the past 12 months, AURX has outperformed S&P 500, delivering a return of +22% compared to the S&P 500's +16% growth.
Stocks Performance
AURX vs S&P 500
Performance Gap
AURX vs S&P 500
Performance By Year
AURX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nuo Therapeutics Inc
Glance View
Nuo Therapeutics, Inc. is a biomedical company. The company is headquartered in Houston, Texas and currently employs 7 full-time employees. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. The firm is marketing its products primarily within the United States. Nuo Therapeutics' s Aurix System produces a platelet rich plasma (PRP), gel at the point of care using the patient’s own platelets and plasma. The Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
